GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Net Current Asset Value

Daiichinkyo Co (Daiichinkyo Co) Net Current Asset Value

: $1.58 (As of Dec. 2023)
View and export this data going back to 2008. Start your Free Trial

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Daiichinkyo Co's net current asset value per share for the quarter that ended in Dec. 2023 was $1.58.

The historical rank and industry rank for Daiichinkyo Co's Net Current Asset Value or its related term are showing as below:

DSNKY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.97   Med: 8.73   Max: 21.4
Current: 20.67

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Daiichinkyo Co was 21.40. The lowest was 2.97. And the median was 8.73.

DSNKY's Price-to-Net-Current-Asset-Value is ranked worse than
83.86% of 607 companies
in the Drug Manufacturers industry
Industry Median: 5.31 vs DSNKY: 20.67

Daiichinkyo Co Net Current Asset Value Historical Data

The historical data trend for Daiichinkyo Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Current Asset Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.57 2.79 2.19 2.09 1.69

Daiichinkyo Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Current Asset Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.76 1.69 1.56 1.65 1.58

Competitive Comparison

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co Price-to-Net-Current-Asset-Value Distribution

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Price-to-Net-Current-Asset-Value falls into.



Daiichinkyo Co Net Current Asset Value Calculation

Daiichinkyo Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Mar. 2023 is calculated as

Net Current Asset Value Per Share(A: Mar. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(11185.118-7953.021-0-0)/1917.34
=1.69

Daiichinkyo Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(14707.264-11680.903-5.362-0)/1917.34
=1.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (OTCPK:DSNKY) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Daiichinkyo Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.